# A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.

> **NCT04953052** · PHASE2 · WITHDRAWN · sponsor: **Exvastat Ltd.**

## Conditions studied

- Acute Respiratory Distress Syndrome
- COVID-19 Acute Respiratory Distress Syndrome
- Covid19
- ARDS
- Pulmonary Oedema

## Interventions

- **DRUG:** Imatinib Mesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04953052
- **Lead sponsor:** Exvastat Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-14
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Number of moderate to severe ARDS patients hospitalised due to COVID19 diminishingly small. Not expected to recruit required minimum number of patients.
- **Last updated:** 2022-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04953052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04953052, "A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04953052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*